Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Waitlist Candidates

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with end-stage liver disease who are listed for liver transplant~* Have failed the non-invasive approach to weight loss to be actively listed for transplant (requiring 2 clinical return visits without weight loss of \>5 kg)~* Body Mass Index (BMI) \>35~* Negative pregnancy test for females who are able to get pregnant and are of child-bearing age~Exclusion Criteria:~* A previous history of gastric or bariatric surgery~* Current or recent (within 6 months) gastric or duodenal ulcers~* Moderate to severe Portal hypertension defined as portal gastropathy graded as \>= to moderate/severe, gastric varices, or esophageal varices graded \> = moderate/large (Patients with varices which have been obliterated may be included).~* Calculated Model of End-stage Liver Disease (MELD) score \>25 or childs score \>10~* The presence of more than one gastric balloon at the same time~* Any inflammatory disease of the gastrointestinal tract including esophagitis, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease.~* A large hiatal hernia or \>5 cm hernia or ≤5 cm with associated severe or intractable gastro-esophageal reflux symptoms.~* A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the delivery catheter and/or an endoscope.~* Achalasia or any other severe motility disorder that may pose a safety risk during removal of the device.~* Gastric mass~* Severe coagulopathy~* Patients who are known to have or suspected to have an allergic reaction to materials contained in ORBERA.~* Serious or uncontrolled psychiatric illness or disorder that could compromise patient understanding of or compliance with follow up visits and removal of the device after 6 months.~* Alcoholism or drug addiction~* Patients who are unable or unwilling to take prescribed proton pump inhibitor medication for the duration of the device implant~* Patients unwilling to participate in an established medically-supervised diet and behavior modification program, with routine medical follow-up.~* Patients receiving aspirin, anti-inflammatory agents, anticoagulants or other gastric irritants, not under medical supervision.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Orbera Intragastric Balloon (Type: EXPERIMENTAL): All subjects will be receiving the ORBERA Intragastric Balloon

Based on this trial design, predict the completion outcome and termination type (if applicable).